Osman Nilab - 18 Apr 2022 Form 3 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Role: Chief Medical Officer
Signature: /s/Osman Nilab
Issuer symbol: ENSC
Transactions as of: 18 Apr 2022
Net transactions value: $0
Form type: 3
Filing time: 04 May 2022, 10:20:59 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ENSC	Stock Option							18 Apr 2022	Common Stock	200,000	$1.07	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 18, 2022, Dr. Osman appointed Chief Medical Officer of Ensysce Biosciences, Inc. In connection with her employment, on April 18, 2022, Dr. Osman was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc., par value $0.0001 per share, with an exercise price of $1.07. Twenty-five percent of the Stock Option is scheduled to vest on April 18, 2023, with the remaining shares vesting in equal monthly installments over the thirty-six months thereafter.

Content

On April 18, 2022, Dr. Osman appointed Chief Medical Officer of Ensysce Biosciences, Inc. In connection with her employment, on April 18, 2022, Dr. Osman was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc., par value $0.0001 per share, with an exercise price of $1.07. Twenty-five percent of the Stock Option is scheduled to vest on April 18, 2023, with the remaining shares vesting in equal monthly installments over the thirty-six months thereafter.